Thousand Oaks:Amgenhasannounced a USD650 millionexpansion of itsU.S.manufacturing network, creating hundreds of new jobs. The planned investment will support increased drug production at the company's biologics manufacturing facility in Juncos and integrate advanced technologies throughout the operations process. It is expected to create nearly 750 jobs, including construction roles and new highly skilled manufacturing jobs. "This expansion underscoresAmgen's commitment toU.S.biomanufacturing and to strengthening the resilience of our global supply chain," saidRobert A. Bradway, chairman and chief executive officer atAmgen. "By growing our capacity to deliver innovative medicines with cutting edge technology in our manufacturing plants, we will not only better serve patients but also create high-quality jobs that reinforce America's leadership in biotechnology." "Amgen's multimillion-dollar expansion reflects a bond of mutual loyalty:Amgen's sustained investment andPuerto Rico'sskilled, resilient workforce reinforcing each other over time," saidPuerto RicoGovernor Jenniffer González Colón. "This new expansion not only strengthensU.S.supply chain security through reshoring, it also opens new horizons for our people as we build an innovation ecosystem that positionsPuerto Ricoas the strongest biopharmaceutical hub inthe United States." "Puerto Ricoboasts more than 60 years of expertise and excellence in the biopharmaceutical sector, supported by highly skilled talent and world-class infrastructure," said Sebastián Negrón Reichard,Puerto RicoSecretary of theDepartment of Economic Development and Commerce. "This investment byAmgenis a testament to how committed we are to advancing a competitive and innovative ecosystem that allows global companies to grow and prosper inPuerto Rico." This announcement builds onAmgen's recent investments, including a$600 millionscience and innovation center inCaliforniaand manufacturing expansions of$900 millioninOhioand$1 billioninNorth Carolina, respectively. Read also:AstraZeneca-Amgen Tezspire recommended for approval in EU for chronic rhinosinusitis with nasal polyps